The stock of NeuroPace Inc (NPCE) has gone down by -42.66% for the week, with a -45.11% drop in the past month and a -52.87% drop in the past quarter. The volatility ratio for the week is 15.36%, and the volatility levels for the past 30 days are 8.23% for NPCE. The simple moving average for the past 20 days is -41.51% for NPCE’s stock, with a -22.68% simple moving average for the past 200 days.
Is It Worth Investing in NeuroPace Inc (NASDAQ: NPCE) Right Now?
Additionally, the 36-month beta value for NPCE is 2.04. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for NPCE is 13.74M and currently, short sellers hold a 0.71% ratio of that float. The average trading volume of NPCE on May 10, 2024 was 108.21K shares.
NPCE) stock’s latest price update
The stock of NeuroPace Inc (NASDAQ: NPCE) has decreased by -36.75 when compared to last closing price of 12.60.Despite this, the company has seen a loss of -42.66% in its stock price over the last five trading days. GlobeNewsWire reported 2024-04-17 that MOUNTAIN VIEW, Calif., April 17, 2024 (GLOBE NEWSWIRE) — NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the first quarter of 2024 after market close on Wednesday, May 8, 2024. The company’s management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Analysts’ Opinion of NPCE
Many brokerage firms have already submitted their reports for NPCE stocks, with Wells Fargo repeating the rating for NPCE by listing it as a “Overweight.” The predicted price for NPCE in the upcoming period, according to Wells Fargo is $20 based on the research report published on March 14, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see NPCE reach a price target of $22. The rating they have provided for NPCE stocks is “Outperform” according to the report published on January 30th, 2024.
Cantor Fitzgerald gave a rating of “Overweight” to NPCE, setting the target price at $11 in the report published on November 10th of the previous year.
NPCE Trading at -42.32% from the 50-Day Moving Average
After a stumble in the market that brought NPCE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.09% of loss for the given period.
Volatility was left at 8.23%, however, over the last 30 days, the volatility rate increased by 15.36%, as shares sank -45.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -52.39% lower at present.
During the last 5 trading sessions, NPCE fell by -42.66%, which changed the moving average for the period of 200-days by +99.25% in comparison to the 20-day moving average, which settled at $13.30. In addition, NeuroPace Inc saw -22.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NPCE starting from ORBIMED ADVISORS LLC, who sale 4,674 shares at the price of $14.03 back on May 03 ’24. After this action, ORBIMED ADVISORS LLC now owns 3,406,335 shares of NeuroPace Inc, valued at $65,576 using the latest closing price.
ORBIMED ADVISORS LLC, the 10% Owner of NeuroPace Inc, sale 8,842 shares at $14.01 during a trade that took place back on May 02 ’24, which means that ORBIMED ADVISORS LLC is holding 3,411,009 shares at $123,876 based on the most recent closing price.
Stock Fundamentals for NPCE
Current profitability levels for the company are sitting at:
- -0.38 for the present operating margin
- 0.74 for the gross margin
The net margin for NeuroPace Inc stands at -0.33. The total capital return value is set at -0.31. Equity return is now at value -150.63, with -30.72 for asset returns.
Based on NeuroPace Inc (NPCE), the company’s capital structure generated 0.84 points at debt to capital in total, while cash flow to debt ratio is standing at -0.24. The debt to equity ratio resting at 5.1. The interest coverage ratio of the stock is -6.15.
Currently, EBITDA for the company is -25.57 million with net debt to EBITDA at -2.56. When we switch over and look at the enterprise to sales, we see a ratio of 4.18. The receivables turnover for the company is 5.94for trailing twelve months and the total asset turnover is 0.7. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.43.
Conclusion
In conclusion, NeuroPace Inc (NPCE) has seen bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
